Cargando…

An inhibitor-driven study for enhancing the selectivity of indirubin derivatives towards leishmanial Glycogen Synthase Kinase-3 over leishmanial cdc2-related protein kinase 3

BACKGROUND: In search of new antiparasitic agents for overcoming the limitations of current leishmaniasis chemotherapy, we have previously shown that 6-bromoindirubin-3'-oxime (6BIO) and several other 6-substituted analogues of indirubin, a naturally occurring bis-indole present in mollusks and...

Descripción completa

Detalles Bibliográficos
Autores principales: Efstathiou, Antonia, Gaboriaud-Kolar, Nicolas, Smirlis, Despina, Myrianthopoulos, Vassilios, Vougogiannopoulou, Konstantina, Alexandratos, Alexandros, Kritsanida, Marina, Mikros, Emmanuel, Soteriadou, Ketty, Skaltsounis, Alexios-Leandros
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2014
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4039064/
https://www.ncbi.nlm.nih.gov/pubmed/24886176
http://dx.doi.org/10.1186/1756-3305-7-234
_version_ 1782318435826401280
author Efstathiou, Antonia
Gaboriaud-Kolar, Nicolas
Smirlis, Despina
Myrianthopoulos, Vassilios
Vougogiannopoulou, Konstantina
Alexandratos, Alexandros
Kritsanida, Marina
Mikros, Emmanuel
Soteriadou, Ketty
Skaltsounis, Alexios-Leandros
author_facet Efstathiou, Antonia
Gaboriaud-Kolar, Nicolas
Smirlis, Despina
Myrianthopoulos, Vassilios
Vougogiannopoulou, Konstantina
Alexandratos, Alexandros
Kritsanida, Marina
Mikros, Emmanuel
Soteriadou, Ketty
Skaltsounis, Alexios-Leandros
author_sort Efstathiou, Antonia
collection PubMed
description BACKGROUND: In search of new antiparasitic agents for overcoming the limitations of current leishmaniasis chemotherapy, we have previously shown that 6-bromoindirubin-3'-oxime (6BIO) and several other 6-substituted analogues of indirubin, a naturally occurring bis-indole present in mollusks and plants, displayed reverse selectivity from the respective mammalian kinases, targeting more potently the leishmanial Cyclin-Dependent Kinase-1 (CDK1) homologue [cdc2-related protein kinase 3 (LCRK3)] over leishmanial Glycogen Synthase Kinase-3 (LGSK-3). This reversal of selectivity in Leishmania parasites compared to mammalian cells makes the design of specific indirubin-based LGSK-3 inhibitors difficult. In this context, the identification of compounds bearing specific substitutions that shift indirubin inhibition towards LGSK-3, previously found to be a potential drug target, over LCRK3 is imperative for antileishmanial targeted drug discovery. METHODS: A new in-house indirubin library, composed of 35 compounds, initially designed to target mammalian kinases (CDKs, GSK-3), was tested against Leishmania donovani promastigotes and intracellular amastigotes using the Alamar blue assay. Indirubins with antileishmanial activity were tested against LGSK-3 and LCRK3 kinases, purified from homologous expression systems. Flow cytometry (FACS) was used to measure the DNA content for cell-cycle analysis and the mode of cell death. Comparative structural analysis of the involved kinases was then performed using the Szmap algorithm. RESULTS: We have identified 7 new indirubin analogues that are selective inhibitors of LGSK-3 over LCRK3. These new inhibitors were also found to display potent antileishmanial activity with GI(50) values of <1.5 μΜ. Surprisingly, all the compounds that displayed enhanced selectivity towards LGSK-3, were 6BIO analogues bearing an additional 3'-bulky amino substitution, namely a piperazine or pyrrolidine ring. A comparative structural analysis of the two aforementioned leishmanial kinases was subsequently undertaken to explain and rationalize the selectivity trend determined by the in vitro binding assays. Interestingly, the latter analysis showed that selectivity could be correlated with differences in kinase solvation thermo dynamics induced by minor sequence variations of the otherwise highly similar ATP binding pockets. CONCLUSIONS: In conclusion, 3'-bulky amino substituted 6-BIO derivatives, which demonstrate enhanced specificity towards LGSK-3, represent a new scaffold for targeted drug development to treat leishmaniasis.
format Online
Article
Text
id pubmed-4039064
institution National Center for Biotechnology Information
language English
publishDate 2014
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-40390642014-05-31 An inhibitor-driven study for enhancing the selectivity of indirubin derivatives towards leishmanial Glycogen Synthase Kinase-3 over leishmanial cdc2-related protein kinase 3 Efstathiou, Antonia Gaboriaud-Kolar, Nicolas Smirlis, Despina Myrianthopoulos, Vassilios Vougogiannopoulou, Konstantina Alexandratos, Alexandros Kritsanida, Marina Mikros, Emmanuel Soteriadou, Ketty Skaltsounis, Alexios-Leandros Parasit Vectors Research BACKGROUND: In search of new antiparasitic agents for overcoming the limitations of current leishmaniasis chemotherapy, we have previously shown that 6-bromoindirubin-3'-oxime (6BIO) and several other 6-substituted analogues of indirubin, a naturally occurring bis-indole present in mollusks and plants, displayed reverse selectivity from the respective mammalian kinases, targeting more potently the leishmanial Cyclin-Dependent Kinase-1 (CDK1) homologue [cdc2-related protein kinase 3 (LCRK3)] over leishmanial Glycogen Synthase Kinase-3 (LGSK-3). This reversal of selectivity in Leishmania parasites compared to mammalian cells makes the design of specific indirubin-based LGSK-3 inhibitors difficult. In this context, the identification of compounds bearing specific substitutions that shift indirubin inhibition towards LGSK-3, previously found to be a potential drug target, over LCRK3 is imperative for antileishmanial targeted drug discovery. METHODS: A new in-house indirubin library, composed of 35 compounds, initially designed to target mammalian kinases (CDKs, GSK-3), was tested against Leishmania donovani promastigotes and intracellular amastigotes using the Alamar blue assay. Indirubins with antileishmanial activity were tested against LGSK-3 and LCRK3 kinases, purified from homologous expression systems. Flow cytometry (FACS) was used to measure the DNA content for cell-cycle analysis and the mode of cell death. Comparative structural analysis of the involved kinases was then performed using the Szmap algorithm. RESULTS: We have identified 7 new indirubin analogues that are selective inhibitors of LGSK-3 over LCRK3. These new inhibitors were also found to display potent antileishmanial activity with GI(50) values of <1.5 μΜ. Surprisingly, all the compounds that displayed enhanced selectivity towards LGSK-3, were 6BIO analogues bearing an additional 3'-bulky amino substitution, namely a piperazine or pyrrolidine ring. A comparative structural analysis of the two aforementioned leishmanial kinases was subsequently undertaken to explain and rationalize the selectivity trend determined by the in vitro binding assays. Interestingly, the latter analysis showed that selectivity could be correlated with differences in kinase solvation thermo dynamics induced by minor sequence variations of the otherwise highly similar ATP binding pockets. CONCLUSIONS: In conclusion, 3'-bulky amino substituted 6-BIO derivatives, which demonstrate enhanced specificity towards LGSK-3, represent a new scaffold for targeted drug development to treat leishmaniasis. BioMed Central 2014-05-20 /pmc/articles/PMC4039064/ /pubmed/24886176 http://dx.doi.org/10.1186/1756-3305-7-234 Text en Copyright © 2014 Efstathiou et al.; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research
Efstathiou, Antonia
Gaboriaud-Kolar, Nicolas
Smirlis, Despina
Myrianthopoulos, Vassilios
Vougogiannopoulou, Konstantina
Alexandratos, Alexandros
Kritsanida, Marina
Mikros, Emmanuel
Soteriadou, Ketty
Skaltsounis, Alexios-Leandros
An inhibitor-driven study for enhancing the selectivity of indirubin derivatives towards leishmanial Glycogen Synthase Kinase-3 over leishmanial cdc2-related protein kinase 3
title An inhibitor-driven study for enhancing the selectivity of indirubin derivatives towards leishmanial Glycogen Synthase Kinase-3 over leishmanial cdc2-related protein kinase 3
title_full An inhibitor-driven study for enhancing the selectivity of indirubin derivatives towards leishmanial Glycogen Synthase Kinase-3 over leishmanial cdc2-related protein kinase 3
title_fullStr An inhibitor-driven study for enhancing the selectivity of indirubin derivatives towards leishmanial Glycogen Synthase Kinase-3 over leishmanial cdc2-related protein kinase 3
title_full_unstemmed An inhibitor-driven study for enhancing the selectivity of indirubin derivatives towards leishmanial Glycogen Synthase Kinase-3 over leishmanial cdc2-related protein kinase 3
title_short An inhibitor-driven study for enhancing the selectivity of indirubin derivatives towards leishmanial Glycogen Synthase Kinase-3 over leishmanial cdc2-related protein kinase 3
title_sort inhibitor-driven study for enhancing the selectivity of indirubin derivatives towards leishmanial glycogen synthase kinase-3 over leishmanial cdc2-related protein kinase 3
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4039064/
https://www.ncbi.nlm.nih.gov/pubmed/24886176
http://dx.doi.org/10.1186/1756-3305-7-234
work_keys_str_mv AT efstathiouantonia aninhibitordrivenstudyforenhancingtheselectivityofindirubinderivativestowardsleishmanialglycogensynthasekinase3overleishmanialcdc2relatedproteinkinase3
AT gaboriaudkolarnicolas aninhibitordrivenstudyforenhancingtheselectivityofindirubinderivativestowardsleishmanialglycogensynthasekinase3overleishmanialcdc2relatedproteinkinase3
AT smirlisdespina aninhibitordrivenstudyforenhancingtheselectivityofindirubinderivativestowardsleishmanialglycogensynthasekinase3overleishmanialcdc2relatedproteinkinase3
AT myrianthopoulosvassilios aninhibitordrivenstudyforenhancingtheselectivityofindirubinderivativestowardsleishmanialglycogensynthasekinase3overleishmanialcdc2relatedproteinkinase3
AT vougogiannopouloukonstantina aninhibitordrivenstudyforenhancingtheselectivityofindirubinderivativestowardsleishmanialglycogensynthasekinase3overleishmanialcdc2relatedproteinkinase3
AT alexandratosalexandros aninhibitordrivenstudyforenhancingtheselectivityofindirubinderivativestowardsleishmanialglycogensynthasekinase3overleishmanialcdc2relatedproteinkinase3
AT kritsanidamarina aninhibitordrivenstudyforenhancingtheselectivityofindirubinderivativestowardsleishmanialglycogensynthasekinase3overleishmanialcdc2relatedproteinkinase3
AT mikrosemmanuel aninhibitordrivenstudyforenhancingtheselectivityofindirubinderivativestowardsleishmanialglycogensynthasekinase3overleishmanialcdc2relatedproteinkinase3
AT soteriadouketty aninhibitordrivenstudyforenhancingtheselectivityofindirubinderivativestowardsleishmanialglycogensynthasekinase3overleishmanialcdc2relatedproteinkinase3
AT skaltsounisalexiosleandros aninhibitordrivenstudyforenhancingtheselectivityofindirubinderivativestowardsleishmanialglycogensynthasekinase3overleishmanialcdc2relatedproteinkinase3
AT efstathiouantonia inhibitordrivenstudyforenhancingtheselectivityofindirubinderivativestowardsleishmanialglycogensynthasekinase3overleishmanialcdc2relatedproteinkinase3
AT gaboriaudkolarnicolas inhibitordrivenstudyforenhancingtheselectivityofindirubinderivativestowardsleishmanialglycogensynthasekinase3overleishmanialcdc2relatedproteinkinase3
AT smirlisdespina inhibitordrivenstudyforenhancingtheselectivityofindirubinderivativestowardsleishmanialglycogensynthasekinase3overleishmanialcdc2relatedproteinkinase3
AT myrianthopoulosvassilios inhibitordrivenstudyforenhancingtheselectivityofindirubinderivativestowardsleishmanialglycogensynthasekinase3overleishmanialcdc2relatedproteinkinase3
AT vougogiannopouloukonstantina inhibitordrivenstudyforenhancingtheselectivityofindirubinderivativestowardsleishmanialglycogensynthasekinase3overleishmanialcdc2relatedproteinkinase3
AT alexandratosalexandros inhibitordrivenstudyforenhancingtheselectivityofindirubinderivativestowardsleishmanialglycogensynthasekinase3overleishmanialcdc2relatedproteinkinase3
AT kritsanidamarina inhibitordrivenstudyforenhancingtheselectivityofindirubinderivativestowardsleishmanialglycogensynthasekinase3overleishmanialcdc2relatedproteinkinase3
AT mikrosemmanuel inhibitordrivenstudyforenhancingtheselectivityofindirubinderivativestowardsleishmanialglycogensynthasekinase3overleishmanialcdc2relatedproteinkinase3
AT soteriadouketty inhibitordrivenstudyforenhancingtheselectivityofindirubinderivativestowardsleishmanialglycogensynthasekinase3overleishmanialcdc2relatedproteinkinase3
AT skaltsounisalexiosleandros inhibitordrivenstudyforenhancingtheselectivityofindirubinderivativestowardsleishmanialglycogensynthasekinase3overleishmanialcdc2relatedproteinkinase3